SUZ12 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2593752	0.61	11/20
SCHEMBL2595868	0.76	9/20
SCHEMBL2590510	0.72	9/20
SCHEMBL2592674	0.68	9/20
SCHEMBL2593584	0.66	9/20
SCHEMBL2595131	0.63	9/20
SCHEMBL2593163	0.58	9/20
SCHEMBL2592959	0.58	9/20
SCHEMBL2594034	0.49	9/20
SCHEMBL2595068	0.75	8/20
SCHEMBL2596078	0.71	8/20
SCHEMBL2590220	0.65	8/20
SCHEMBL2588638	0.64	8/20
SCHEMBL2596014	0.63	8/20
SCHEMBL2596016	0.63	8/20
SCHEMBL123435	0.35	8/20
SCHEMBL989559	0.32	8/20
SCHEMBL2590359	0.78	7/20
SCHEMBL2588434	0.72	7/20
SCHEMBL2588714	0.67	7/20

Clinical trials — most relevant to SUZ12 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer	PHASE1/PHASE2	RECRUITING
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	PHASE2	COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	PHASE2	ACTIVE_NOT_RECRUITING
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.	PHASE2	RECRUITING
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML	PHASE1/PHASE2	COMPLETED
Study of ORIC-944 in Patients With Metastatic Prostate Cancer	PHASE1	RECRUITING
Tazemetostat and Palbociclib With CPX-351for R/R AML	PHASE1	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Hippotherapy in Children With Spinal Muscular Atrophy	nan	RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Characterization of Angelman Syndrome	nan	COMPLETED
Mechanisms of Immune Deficiency	nan	UNKNOWN
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes	nan	COMPLETED
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Italian Angelman Syndrome Registry	nan	COMPLETED
Prevalence of the c.853delT Mutation of the HOXB13 Gene in Prostate Cancer in Martinique	nan	COMPLETED
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders	nan	NOT_YET_RECRUITING
Better Delineation of BCL11B Related Phenotype and Epigenetic Signature.	nan	COMPLETED
Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SUZ12 binder may also engage these)

Protein	Name	Similarity
Q80U70	—	1.000	Q80U70 →
Q0VA03	—	0.991	Q0VA03 →
Q5R724	—	0.973	Q5R724 →
B0R1D5	—	0.973	B0R1D5 →
Q7TT00	—	0.967	Q7TT00 →
Q8C735	—	0.966	Q8C735 →
Q5TKA1	—	0.966	Q5TKA1 →
Q9BZ29	—	0.965	Q9BZ29 →
Q4R8N2	—	0.964	Q4R8N2 →
Q66HC7	—	0.964	Q66HC7 →
Q8BKT7	—	0.963	Q8BKT7 →
Q9R1D7	—	0.961	Q9R1D7 →
Q6DC60	—	0.961	Q6DC60 →
Q08BT5	—	0.960	Q08BT5 →
Q68FX7	—	0.960	Q68FX7 →
Q9HBM0	—	0.960	Q9HBM0 →
Q9P260	—	0.960	Q9P260 →
Q8BIK4	—	0.960	Q8BIK4 →
Q5VTB9	—	0.960	Q5VTB9 →
A4IFQ0	—	0.960	A4IFQ0 →
Q13769	—	0.960	Q13769 →
Q8HXD5	—	0.959	Q8HXD5 →
Q86V25	—	0.959	Q86V25 →
A9JRA0	—	0.959	A9JRA0 →
Q148V7	—	0.959	Q148V7 →
Q9D772	—	0.959	Q9D772 →
Q96PE3	—	0.958	Q96PE3 →
Q6PH81	—	0.958	Q6PH81 →
Q5JSJ4	—	0.958	Q5JSJ4 →
Q8WXI2	—	0.958	Q8WXI2 →